Regulatory data workflows
Capture, map, verify, and route approved information with field-level source references and an explicit exception queue.
Scope the workflowMake regulatory data easier to use without hiding how it got there.
We help emerging biotech and pharmaceutical teams turn approved source material into review-ready data, documents, trackers, and evidence structures.
One control model, several bounded applications.
Ex-US support is an important entry point, not a claim that one workflow fits every regulated function. The source set, intended use, reviewers, systems, and exclusions are scoped each time.
Ex-US readiness
Assess reuse, localization gaps, responsibilities, dependencies, and next actions before an international work package grows.
Review the sprintEx-US execution
Manage bounded dossier, submission-operations, authority-response, labeling, or lifecycle work that can be delivered remotely.
Review the scopeQA and marketing operations
Founder-led discovery only. Bounded document, evidence, routing, and data-hygiene problems remain proof-gated; accountable quality and MLR decisions stay with client roles.
Discuss a proof-gated problemThe workflow supports the reviewer. It does not become the reviewer.
Durability can prepare, coordinate, and make the evidence easier to inspect. The client and its qualified professionals retain regulated interpretation, medical and legal review, quality decisions, release authority, and final approval.
Approved source set
Only permitted records, versions, systems, and data classes enter the workflow.
Measured test
Representative examples, error types, thresholds, and exceptions are agreed before use.
Named review
People can see the source, edit the output, and stop or return the work.
Evidence record
Material output retains its source, changes, exceptions, reviewer, and state.
Use the synthetic demo to inspect the product direction.
The pharma dossier demo is ungated and preloaded. It lets a buyer see source material, CTD structure, drafting, review, and a visible demo-versus-production boundary before sharing any contact information.
See the Pharma Workflow DemoApproved public-demo boundary
AreaDemo stateBoundary
Source dataSynthetic fixturesPublic
UploadsDisabled for public useClosed
IntegrationsIllustrative directionScoped
ValidationDepends on intended useClient-led
What we will not imply.
A controlled workflow can support a regulated process. It does not become compliant, validated, secure, private, or fit for use because of a model name, integration, audit log, or deployment label.
No blanket compliance promise
Part 11, GxP, privacy, security, and validation claims require the actual intended use, client environment, implementation evidence, and accountable owners.
No unsupervised judgment
The workflow does not make medical, legal, regulatory, quality, safety, release, or submission-approval decisions for the client.
No unapproved data intake
Confidential, patient-identifiable, safety-case, or controlled records are not accepted until systems and handling rules are approved in writing.
Start with one life-sciences workflow.
Bring the operational bottleneck, the milestone, and the non-confidential boundary. We will determine whether a workflow pilot, readiness sprint, or ex-US work package is the sensible next step.